In medtech, including the spine business, few goals generate as much obsession as obtaining FDA clearance in the United States or CE marking under MDR in Europe. For many startups, that milestone eventually becomes the company’s central focus. Everything revolves around approval: the product, trials, documentation, investors, timelines, and resources.
The problem is that many end up confusing regulatory approval with commercial viability. And they are not the same thing.
A startup can reach the end of the process with a very interesting product, a solid technical foundation, and regulatory approval in hand, while still being far from having built a real company. It has an approved device, yes. But it is missing everything else: team, strategy, market access, commercial structure, and above all, a business model.
That is one of the most common mistakes in the sector. The regulator may say yes. The market may not.
Approval Does Not Mean Adoption
Many companies go through the regulatory process as if it were the ultimate test. And in one sense, it is, but only on one level. It proves that the product can be commercialized. It does not prove that it will be purchased, implanted, defended internally within a hospital, or adopted in a sustained way.
That is where the real problem begins.
Too many startups leave until later the questions that should have been addressed much earlier: who actually buys, who influences the decision, who blocks it, which budget it comes from, what impact it has on workflow, what training it requires, what economic evidence the hospital needs, and whether the price fits the real purchasing logic.
When those questions appear after approval, they are no longer a detail. They are a bill.
The Product Is Not the Company
Another common misconception is to think that a great product will eventually find its place on its own. But in medtech, a good device is not enough. Hospitals do not buy clinical innovation alone. They also buy ease of implementation, operational safety, economic logic, support, reliable supply, and confidence in the supplier.
That is why so many startups reach the market with approved technology but an incomplete company behind it. No proper commercial team. No clear channel strategy. No value proposition tailored to each stakeholder. No realistic view of how adoption is built beyond the enthusiasm of one or two surgeons.
And that is where the real gap appears: the business model.
The Business Model, the Great Overlooked Factor
In too many cases, the business model is treated like a pitch deck slide rather than a central part of the company. But in medtech, it is decisive. It defines how value is captured, how commercial friction is reduced, and how growth is sustained in an environment of slow and complex adoption.
It is not enough to have a price. The company needs to know whether that price fits hospital reality. Whether it adds cost or shifts it. Whether it requires upfront investment. Whether it needs consumables, clinical support, training, or operational changes. Whether the hospital clearly understands why it should incorporate it.
Too many startups discover too late that their product works better than their commercial logic.Approval opens the door, but it does not build the business.
The Right Question
The question a startup should ask itself is not only whether it will achieve FDA clearance or MDR approval. The real question is another one: when approval arrives, will we actually be ready to win in the market?
In too many cases, the answer is no.
Because in medtech, regulation can authorize a product. But it does not replace strategy, it does not create an organization, and it does not invent a business model. And that small but brutal detail is what leaves so many startups with an approved device and a company that still has not really been built.
###